OKYO Pharma Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Quarter	H2 2026	H1 2026	H2 2025	H1 2025	H2 2024	H1 2024	H2 2023	H1 2023	H2 2022	H1 2022
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Sep '24 Sep 30, 2024	Mar '24 Mar 31, 2024	Sep '23 Sep 30, 2023	Mar '23 Mar 31, 2023	Sep '22 Sep 30, 2022	Mar '22 Mar 31, 2022	Sep '21 Sep 30, 2021
Cost of Revenue	4.14	2.55	3.71	1.12	3.37	4.13	3.86	2.69	2.47	2.19
Gross Profit	-4.14	-2.55	-3.71	-1.12	-3.37	-4.13	-3.86	-2.69	-2.47	-2.19
Research & Development	1.85	-0.04	0.04	2.22	3.64	4.6	3.69	2.39	1.16	0.47
Operating Expenses	1.85	-0.04	0.04	2.22	3.64	4.6	3.69	2.39	1.16	0.47
Operating Income	-6	-2.5	-3.75	-3.34	-7.02	-8.73	-7.55	-5.08	-3.63	-2.66
Interest Expense	-0.39	-0.08	-0.11	-0.76	-1.05	-	-0.1	-	-	-0
Interest & Investment Income	0.03	-	0.01	-	-	-	-	-	0	-
Other Non Operating Income (Expenses)	-0	-	-0.01	-	-	-	-	-	-	-
EBT Excluding Unusual Items	-6.35	-2.59	-3.87	-4.1	-8.07	-8.73	-7.65	-5.08	-3.63	-2.66
Pretax Income	-6.35	-2.59	-3.87	-4.1	-8.07	-8.73	-7.65	-5.08	-3.63	-2.66
Income Tax Expense	0.01	0	-1.85	-1.42	-0.06	0.08	-0.01	-	-0.61	-0.18
Earnings From Continuing Operations	-6.36	-2.59	-2.03	-2.68	-8.01	-8.82	-7.64	-5.08	-3.02	-2.48
Net Income	-6.36	-2.59	-2.03	-2.68	-8.01	-8.82	-7.64	-5.08	-3.02	-2.48
Net Income to Common	-6.36	-2.59	-2.03	-2.68	-8.01	-8.82	-7.64	-5.08	-3.02	-2.48
Net Income Growth (YoY)	-	-	-	-	-	-	-	-	-	-
Shares Outstanding (Basic)	37	37	45	34	33	26	23	22	16	14
Shares Outstanding (Diluted)	37	37	45	34	33	26	23	22	16	14
Shares Change (YoY)	-17.86%	11.46%	37.70%	30.56%	44.17%	18.81%	41.86%	54.52%	52.75%	38.06%
EPS (Basic)	-0.17	-0.07	-0.04	-0.08	-0.24	-0.34	-0.33	-0.23	-0.19	-0.18
EPS (Diluted)	-0.17	-0.07	-0.04	-0.08	-0.24	-0.34	-0.33	-0.23	-0.19	-0.18
EPS Growth (YoY)	-	-	-	-	-	-	-	-	-	-

Additional Metrics

Fiscal Quarter	H2 2026	H1 2026	H2 2025	H1 2025	H2 2024	H1 2024	H2 2023	H1 2023	H2 2022	H1 2022
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Sep '24 Sep 30, 2024	Mar '24 Mar 31, 2024	Sep '23 Sep 30, 2023	Mar '23 Mar 31, 2023	Sep '22 Sep 30, 2022	Mar '22 Mar 31, 2022	Sep '21 Sep 30, 2021
Free Cash Flow	-4.41	-1.53	-1.57	-0.24	-2.7	-6.79	-4.11	-3.24	-2.61	-2.94
Free Cash Flow Per Share	-0.12	-0.04	-0.04	-0.01	-0.08	-0.26	-0.18	-0.15	-0.16	-0.21
EBITDA	-6	-2.5	-3.75	-3.34	-7.01	-8.73	-7.55	-5.07	-3.63	-2.66
D&A For EBITDA	0	0	0	0	0	0	0	0	0	0
EBIT	-6	-2.5	-3.75	-3.34	-7.02	-8.73	-7.55	-5.08	-3.63	-2.66

SEC Filings: 10-K · 10-Q